Simplify diabetes management for your patients
Healthcare providers (HCPs) like you who care for people with diabetes are talking with more and more patients who are interested in the benefits of an insulin pump. Among Canadian HCPs, complexity is the #1 reason that pumps are not recommended for some patients.1
Pod Therapy is something you might consider instead.
Omnipod® provides a simple, effective alternative to both MDI and tubed pumps
for patients requiring insulin.
One small, tubeless, wearable, and waterproof* Pod provides up to 3 days (72 hours) of non-stop insulin.
The Personal Diabetes Manager is not waterproof.
Actual Pod size: 3.9 cm wide x 5.2 cm long x 1.45 cm high
Insulin Management System
The discreet, tubeless and waterproof* way to deliver insulin for your patients
Insulin Management System
The original Omnipod® System with built-in FreeStyle® Lite blood glucose meter
Pod therapy can simplify diabetes management for your patients
Give them the benefits of tubeless freedom.
They get a 2 part management system that is:
- replaces 14 daily needle injections with continuous insulin delivery for up to 3 days (72 hours)
Other system benefits include:
- Simple to set up and train patients
- Quick access to patient data from anywhere with Glooko®
- Intuitive screen navigation and quick treatment modifications
- 99% of users chose to stay on Omnipod® Insulin Management System therapy after 3 years2
- Virtually pain-free automated cannula insertion
Have a patient ready to experience the tubeless freedom of Omnipod®?
“ The Pod is a revolution in insulin therapy. No tubes, less needle sticks, constant insulin delivery for 3 days — no disconnect. All of these factors improve adherence among people with diabetes and, as a result, dramatically improve clinical outcomes and quality of life.”
is an award-winning endocrinology, diabetes and metabolism specialist and founder of the Beaumont Endocrine Center
Dr. Brennan is a paid consultant of Insulet Corporation, however, the views expressed in this testimony are his own.
1. Data on File, Insulet Canada, 2022.
2. Leelarathna L., et al. Diabet Med. 2017;34(10):1372–1379. Observational, retrospective study which was evaluated long-term HbA1c changes on insulin pump therapy (Medtronic, Insulet, Roche and Animas). 508 individuals starting pump therapy, 94% had type 1 diabetes. Median follow-up was 3.7 years. Study conducted in UK.
FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions and used with permission.